GO:0051020 GTPase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051020 GTPase binding describes the molecular function of selectively binding to a GTPase, any enzyme that hydrolyzes GTP.
• GTPases act as molecular switches, and their binding partners determine when and where signals are turned on or off [2,6].
• GTPase binding is central to membrane traffic, where networks of GTPases and their effectors coordinate vesicle formation, transport and fusion.
• Dysregulated GTPase binding contributes to cancer, infectious disease and mitochondrial dysfunction [5,8].
• Key experimental approaches include GTPase activity assays, nucleotide-binding measurements, knockout and point-mutation cell models, and CRISPR screening [1,3,7].
• EDITGENE provides knockout, point-mutation, knock-in, overexpression and CRISPR library screening services to dissect GTPase-binding mechanisms.
Description
GO:0051020 GTPase binding is a molecular function term that describes the selective interaction of a protein or other molecule with a GTPase, defined as any enzyme that catalyzes the hydrolysis of GTP. GTPases are widespread regulators of cellular processes, and their binding partners include guanine nucleotide exchange factors, GTPase-activating proteins, effectors and structural partners that together form signaling networks [2,6]. Because GTP binding and hydrolysis cycle the GTPase between active and inactive states, proteins that bind GTPases can control the timing, location and intensity of downstream signals [2,6]. This makes GTPase binding a recurring theme in cell biology, from membrane trafficking to mitochondrial regulation and host-pathogen interactions [5,6]. Researchers study GTPase binding to understand how cells organize signaling, how pathogens exploit host GTPases and how mutations in GTPase pathways cause disease [3,5,8]. The term is also practically important because GTPase-binding proteins are common drug targets and are frequently interrogated by CRISPR-based functional genomics [3,8].
GTPase binding At A Glance
| GO ID | GO:0051020 |
|---|---|
| GO term | GTPase binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a GTPase, any enzyme that catalyzes the hydrolysis of GTP |
| Example GTPase families | RAS superfamily small GTPases, large GTPases such as guanylate-binding proteins and mitochondrial GTPases |
| Related processes | Membrane traffic, signal transduction, mitochondrial regulation, host-pathogen interactions |
| Representative assays | GTPase activity assays, nucleotide-binding measurements, co-immunoprecipitation, CRISPR-based perturbation |
What Is GO:0051020?
In the Gene Ontology, GO:0051020 GTPase binding is defined as binding to a GTPase, any enzyme that catalyzes the hydrolysis of GTP. In practice, this means the annotated protein or molecule physically interacts with a GTPase, often in a nucleotide-dependent manner, and this interaction may regulate the GTPase's activity, localization or effector coupling [2,6]. The term covers binding to small GTPases such as RAS superfamily members as well as to large GTPases including guanylate-binding proteins and mitochondrial GTPases [5,7,8].
Why Is GTPase binding Important in Cell Biology?
GTPase binding is important because it determines how GTPase switches are connected to cellular outcomes. GTPases cycle between GTP-bound active and GDP-bound inactive states, and the proteins that bind them decide which effectors are engaged and where signals are delivered [2,6]. In membrane traffic, GTPase networks built on binding interactions control vesicle budding, tethering and fusion, so disrupting these interactions can block transport and organelle identity. In disease, altered GTPase binding can drive oncogenic signaling through RAS effector pathways or support pathogen survival, as seen with the conserved GTPase Obg in methicillin-resistant Staphylococcus aureus [3,8]. Mitochondrial GTPases such as NOA1 are activated by binding to G-quadruplex RNA, linking GTPase binding to mitochondrial gene expression and stress responses. Therefore, mapping GTPase-binding interactions provides mechanistic insight and identifies candidate targets for therapeutic intervention [3,5,8].
• GTPase binding controls the spatial and temporal output of GTPase signaling switches.
• It underlies membrane traffic networks that organize vesicle transport and organelle identity.
• It is relevant to cancer because RAS GTPase signaling to alternative effector pathways depends on binding interactions.
• It contributes to infectious disease biology, as shown for the conserved GTPase Obg in methicillin-resistant Staphylococcus aureus.
• It links RNA structure to mitochondrial function through G-quadruplex RNA binding to the GTPase NOA1.
• It can be studied with purified proteins and nucleotide analogs, as demonstrated for human guanylate-binding protein 1.
• It provides a framework for understanding how GTPases are regulated by accessory proteins and effectors [2,6].
• It is a tractable target class for CRISPR knockout, point-mutation and overexpression screens [3,8].
• It helps explain disease mechanisms when GTPase-binding interfaces are mutated or hijacked [3,5,8].
• It supports drug discovery by defining interaction surfaces that can be perturbed [3,8].
Molecular Mechanism of GTPase binding
Nucleotide-dependent recognition of GTPases
In simple terms: Binding partners often prefer the GTP-bound or GDP-bound form of a GTPase, so the nucleotide state acts like a switch.
GTPases cycle between GTP-bound and GDP-bound states, and many binding proteins recognize one state preferentially, which allows them to act as effectors or regulators [2,6]. For example, small GTPase networks in membrane traffic rely on nucleotide-dependent recruitment of effectors and regulators. Direct nucleotide-binding studies on human guanylate-binding protein 1 show how GTP binding and hydrolysis can be measured and how self-stimulated GTPase activity is coupled to the nucleotide cycle. In some cases, binding to a non-protein ligand such as G-quadruplex RNA can activate a mitochondrial GTPase, as reported for NOA1.
Effector coupling and signal transmission
In simple terms: Once a binding partner grabs an active GTPase, it can pass the signal to downstream pathways.
GTPase-binding proteins frequently serve as effectors that relay signals from active GTPases to downstream targets [2,6]. RAS GTPase signaling to alternative effector pathways illustrates how different binding partners can route a single GTPase into distinct outputs. In membrane traffic, GTPase networks coordinate multiple effectors to specify vesicle identity and fusion events. Thus, the molecular function of GTPase binding is not just attachment but selective coupling to specific cellular responses [2,6,8].
Regulation by accessory proteins and cofactors
In simple terms: Other proteins and small molecules can strengthen, weaken or time the interaction between a GTPase and its binding partner.
Guanine nucleotide exchange factors and GTPase-activating proteins regulate the nucleotide state of GTPases, thereby indirectly controlling which binding partners can engage [2,6]. Cofactors such as metal ions and nucleotides can influence binding, as seen in GTPase activity assays where nucleotide and ion conditions are carefully controlled [1,7]. In Entamoeba histolytica, a calcium-binding protein EhCaBP6 was characterized as a novel GTPase, showing that GTPase activity and binding can be modulated by calcium-binding modules. These layers of regulation ensure that GTPase binding is context-dependent [1,2,6].
Structural and biophysical basis of binding
In simple terms: The shape and chemistry of the GTPase surface determine which partners can bind and how tightly.
Biophysical methods such as nucleotide-binding measurements and GTPase activity assays provide quantitative readouts of GTPase interactions and catalysis [1,7]. For human guanylate-binding protein 1, methods were developed to measure nucleotide binding and self-stimulated GTPase activity, which are prerequisites for understanding partner binding. Structural and biochemical studies of GTPase networks in membrane traffic have revealed how binding interfaces select specific effectors. These approaches are essential for defining the molecular function of GO:0051020 in mechanistic terms [1,6,7].
Pathogen and host GTPase-binding strategies
In simple terms: Some microbes depend on GTPase binding for survival, making these interactions drug targets.
The conserved GTPase Obg in methicillin-resistant Staphylococcus aureus binds GTP, and artesunate perturbs this binding, alleviating antibiotic resistance. This demonstrates that small molecules can interfere with GTPase binding and that such interference can have therapeutic consequences. In parallel, host GTPases are targeted by pathogens and by cellular regulatory networks, as reviewed for small GTPases. Therefore, GTPase binding is both a basic cell-biology mechanism and an antimicrobial target space [2,3].
Key Genes Involved in GO:0051020 GTPase binding
The following genes and proteins are representative of GTPase binding biology, including GTPases, their regulators and their binding partners.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HRAS | Small GTPase in RAS signaling | Model for GTPase binding and effector coupling in cancer |
| KRAS | Small GTPase in RAS signaling | Frequently mutated in cancer; binding to effectors is a therapeutic focus |
| NRAS | Small GTPase in RAS signaling | Studied for alternative effector pathway binding |
| GBP1 | Large GTPase with self-stimulated GTPase activity | Nucleotide binding and GTPase assays define binding mechanisms |
| NOA1 | Mitochondrial GTPase activated by G-quadruplex RNA | Links RNA binding to GTPase activation |
| Obg | Conserved bacterial GTPase | GTP binding is targeted by artesunate in MRSA |
| EhCaBP6 | Calcium-binding protein with GTPase activity | Novel GTPase from Entamoeba histolytica |
| RAB family | Small GTPases in membrane traffic | Central to GTPase networks in vesicle transport |
| ARF family | Small GTPases in membrane traffic | Regulate coat recruitment and vesicle budding |
| RHO family | Small GTPases in cytoskeletal signaling | Binding partners control actin dynamics |
| RAN | Small GTPase in nucleocytoplasmic transport | Binding to import/export factors is nucleotide-dependent |
| SAR1 | Small GTPase in ER-to-Golgi transport | Model for GTPase binding in COPII vesicle formation |
| Rab11 | Small GTPase in recycling endosomes | Effector binding specifies membrane identity |
| Rac1 | Small GTPase in cell migration | Effector binding links GTPase to cytoskeleton |
| Cdc42 | Small GTPase in polarity | Binding partners regulate polarity complexes |
| Kainate binding protein | Glutamate receptor-like protein | Chick kainate binding protein lacks GTPase activity, a negative control for GTPase annotation |
How Is GTPase binding Regulated?
GTPase binding is regulated at multiple levels. The nucleotide state of the GTPase, controlled by guanine nucleotide exchange factors and GTPase-activating proteins, determines which binding partners can engage [2,6]. Accessory proteins and post-translational modifications can alter binding interfaces, and in some cases RNA ligands such as G-quadruplexes activate GTPases directly. Calcium-binding modules can also influence GTPase activity, as shown for EhCaBP6. In bacteria, small molecules like artesunate can perturb GTP binding of Obg, indicating that GTPase binding is druggable. Together, these mechanisms ensure that GTPase binding is dynamic and context-specific [1,2,3,5,6].
GTPase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer, RAS pathway activation | Knockout and point-mutation cell lines to test effector binding |
| HRAS | Cancer, RAS signaling | Overexpression and knock-in models for binding studies |
| Obg | MRSA antibiotic resistance | Bacterial knockout and point-mutation strains for GTP binding assays |
| NOA1 | Mitochondrial dysfunction | Knockout and tagged knock-in cells for RNA-binding and GTPase assays |
| EhCaBP6 | Amoebiasis biology | Overexpression and point-mutation models for GTPase activity |
Cancer and RAS pathway dysregulation
RAS GTPases are among the most frequently mutated oncogenes, and their signaling to alternative effector pathways depends on selective binding interactions. Understanding how RAS proteins bind effectors is therefore central to cancer biology and to the development of inhibitors that block these interactions. GTPase binding assays and CRISPR models are used to test whether specific binding interfaces are required for transformation.
Infectious disease and antimicrobial resistance
The conserved GTPase Obg in methicillin-resistant Staphylococcus aureus binds GTP, and artesunate perturbs this binding, alleviating antibiotic resistance. This illustrates how targeting GTPase binding can restore antibiotic efficacy. GTPase-binding proteins in pathogens are therefore candidate drug targets.
Mitochondrial dysfunction and RNA-linked GTPase regulation
The mitochondrial GTPase NOA1 is activated by binding to G-quadruplex RNA, linking GTPase binding to mitochondrial gene expression and stress responses. Disruption of such RNA-GTPase interactions could contribute to mitochondrial dysfunction. This area is relevant to neurodegenerative and metabolic diseases where mitochondrial function is impaired.
Neurological and receptor-related GTPase annotation
The chick kainate binding protein lacks GTPase activity, highlighting the importance of experimental validation when annotating GTPase function. This negative example helps researchers avoid misannotation of GTPase binding or activity in receptor-like proteins. It also underscores the need for direct biochemical assays in neurological protein studies.
From GTPase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for GTPase binding? | CRISPR knockout cell line [3,8] |
| Does a specific residue mediate GTPase binding? | Point-mutation knock-in cell line [3,8] |
| Can a binding interface be tagged for imaging? | Tagged knock-in cell line |
| Does overexpression alter GTPase signaling? | Overexpression cell model |
| Which genes modify GTPase binding phenotypes? | CRISPR library screening [3,8] |
| Does a GTPase bind RNA or other ligands? | Biochemical binding assay with purified protein [5,7] |
How to Study the GTPase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTPase activity assay | Rate of GTP hydrolysis | Confirm GTPase activity and regulation [1,7] |
| Nucleotide-binding assay | Affinity for GTP/GDP | Characterize nucleotide-dependent binding |
| Co-immunoprecipitation | Physical interaction between proteins | Identify GTPase-binding partners [2,6] |
| G-quadruplex RNA binding assay | RNA-protein interaction | Study NOA1 activation by RNA |
| CRISPR knockout | Gene requirement | Test if a gene is needed for GTPase binding [3,8] |
| CRISPR point mutation | Residue-specific function | Map binding interfaces [3,8] |
| CRISPR library screen | Genome-wide modifiers | Discover regulators of GTPase binding [3,8] |
| Live-cell imaging | Localization and dynamics | Track tagged GTPases and partners [5,6] |
GTPase activity and nucleotide-binding assays
Direct measurement of GTP hydrolysis and nucleotide binding is the gold standard for characterizing GTPases and their binding partners [1,7]. Methods for human guanylate-binding protein 1 include nucleotide-binding and self-stimulated GTPase activity assays that can be adapted to other GTPases. These assays are essential to confirm that a protein is a GTPase and to test whether binding partners alter catalysis [1,7].
Binding interaction assays
Co-immunoprecipitation, pull-down and surface-binding assays can detect physical interactions between GTPases and candidate binding proteins [2,6]. Nucleotide-dependent binding can be tested by loading GTPases with non-hydrolyzable GTP analogs or GDP [2,6]. For RNA-binding GTPases such as NOA1, G-quadruplex RNA binding assays are used.
CRISPR-based functional genomics
CRISPR knockout and point-mutation screens can identify genes required for GTPase binding and downstream phenotypes [3,8]. Library screening is particularly useful for discovering modifiers of RAS effector binding or bacterial GTPase dependency [3,8]. These approaches link genotype to binding function at scale [3,8].
Imaging and proteomics
Tagged knock-in cell lines enable live-cell imaging of GTPase localization and binding dynamics [5,6]. Proteomics can identify binding partners and post-translational modifications that regulate interactions. Combining imaging with proteomics provides spatial and compositional information about GTPase-binding complexes [5,6].
How CRISPR Can Be Used to Study GO:0051020 GTPase binding
Knockout
CRISPR knockout cell lines remove a candidate GTPase or binding partner to test whether it is required for a specific interaction or downstream phenotype [3,8]. For example, knocking out a RAS effector can reveal whether GTPase binding to that effector is necessary for signaling. In bacteria, knockout of Obg can be used to study GTP binding and antibiotic resistance.
Point Mutation
Point-mutation knock-in models introduce specific amino acid changes to disrupt or enhance GTPase binding without removing the entire protein [3,8]. This is useful for testing whether a single residue in a binding interface is critical [3,8]. Such models are especially valuable for RAS-family GTPases where effector binding specificity matters.
Knock-in
Tagged knock-in cell lines express a GTPase or binding partner with an epitope or fluorescent tag from its endogenous locus. This allows imaging and biochemical purification of native complexes [5,6]. Knock-in of disease-relevant mutations can also model altered GTPase binding in a physiological context [5,8].
Overexpression
Overexpression models increase the level of a GTPase or binding partner to test gain-of-function effects on signaling. They are useful for detecting dominant effects and for producing protein for biochemical assays [1,7]. Overexpression of EhCaBP6, for example, can be used to study its GTPase activity.
How EDITGENE Supports GTPase binding Research
Researchers studying GTPase binding-related genes often need to determine whether a candidate gene is causally involved in a specific interaction or phenotype. EDITGENE provides publication-ready CRISPR models and screening services to move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for GTPase binding research.
Frequently Asked Questions About GTPase binding
What is GO:0051020 GTPase binding?
GO:0051020 GTPase binding is a Gene Ontology molecular function term defined as binding to a GTPase, any enzyme that catalyzes the hydrolysis of GTP.
What genes are involved in GTPase binding?
Representative genes include HRAS, KRAS, NRAS, GBP1, NOA1, Obg, EhCaBP6 and members of the RAB, ARF, RHO and RAN families [1,2,3,5,6,7,8].
Why is GTPase binding important in cell biology?
It controls when and where GTPase switches engage effectors, which is central to membrane traffic, signal transduction and mitochondrial regulation [2,5,6].
How is GTPase binding measured experimentally?
Common methods include GTPase activity assays, nucleotide-binding assays, co-immunoprecipitation and CRISPR-based perturbation [1,3,7].
What diseases are linked to GTPase binding?
Cancer through RAS effector pathways, infectious disease through bacterial GTPases like Obg, and mitochondrial dysfunction through NOA1 [3,5,8].
Can CRISPR be used to study GTPase binding?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are widely used to test GTPase binding mechanisms [3,5,8].
What is the role of RAS GTPase binding in cancer?
RAS GTPases bind alternative effector pathways, and these interactions are studied as therapeutic targets in cancer.
How does NOA1 GTPase binding work?
NOA1 is a mitochondrial GTPase activated by binding to G-quadruplex RNA, linking RNA structure to GTPase function.
What is the difference between GTPase activity and GTPase binding?
GTPase activity is the hydrolysis of GTP, while GTPase binding is the physical interaction with a GTPase; the two are related but distinct annotations [1,4,7].
Which model system is best for GTPase binding studies?
The choice depends on the question: purified proteins for biochemistry, knockout cells for requirement, and tagged knock-in cells for imaging [1,5,7].
Conclusion
GO:0051020 GTPase binding captures a fundamental molecular function that connects GTPase switches to cellular outcomes. From membrane traffic networks to RAS effector signaling and mitochondrial RNA-linked activation, GTPase binding is a recurring mechanism in health and disease [2,5,6,8]. CRISPR-based models and biochemical assays provide the tools to dissect these interactions with precision [1,3,7]. Continued research on GTPase binding will inform therapeutic strategies in cancer, infectious disease and mitochondrial disorders [3,5,8].
References
- 1. Verma D et al.. 2020. Ca(2+)-binding protein from Entamoeba histolytica (EhCaBP6) is a novel GTPase.. Biochem Biophys Res Commun 527(3):631-637 PMID: 32423808
- 2. Reiner DJ et al.. 2018. Small GTPases.. WormBook 2018:1-65 PMID: 27218782
- 3. Chakraborty A et al.. 2025. Artesunate Perturbs GTP Binding of the Conserved GTPase Obg Thereby Alleviating Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus.. ACS Infect Dis 11(5):1190-1202 PMID: 40278541
- 4. Tasca CI et al.. 1999. Chick kainate binding protein lacks GTPase activity.. Neuroreport 10(9):1981-3 PMID: 10501544
- 5. Al-Furoukh N et al.. 2013. Binding to G-quadruplex RNA activates the mitochondrial GTPase NOA1.. Biochim Biophys Acta 1833(12):2933-2942 PMID: 23933583
- 6. Mizuno-Yamasaki E et al.. 2012. GTPase networks in membrane traffic.. Annu Rev Biochem 81:637-59 PMID: 22463690
- 7. Kunzelmann S et al.. 2005. Nucleotide binding and self-stimulated GTPase activity of human guanylate-binding protein 1 (hGBP1).. Methods Enzymol 404:512-27 PMID: 16413296
- 8. Singh S et al.. 2020. RAS GTPase signalling to alternative effector pathways.. Biochem Soc Trans 48(5):2241-2252 PMID: 33125484
